NervGen Financial Statements From 2010 to 2024

NGEN Stock  CAD 2.87  0.08  2.87%   
NervGen Pharma financial statements provide useful quarterly and yearly information to potential NervGen Pharma Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NervGen Pharma financial statements helps investors assess NervGen Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NervGen Pharma's valuation are summarized below:
Market Capitalization
201.8 M
Earnings Share
(0.38)
There are over one hundred nineteen available fundamental ratios for NervGen Pharma, which can be analyzed over time and compared to other ratios. All traders should should check NervGen Pharma's last-minute fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to drop to about 51.9 M in 2024. Enterprise Value is likely to drop to about 47.2 M in 2024
Check NervGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NervGen Pharma's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 4.9 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NervGen financial statements analysis is a perfect complement when working with NervGen Pharma Valuation or Volatility modules.
  
This module can also supplement various NervGen Pharma Technical models . Check out the analysis of NervGen Pharma Correlation against competitors.

NervGen Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets11.3 M13.2 M5.6 M
Slightly volatile
Other Current Liabilities12.3 M11.7 M2.3 M
Slightly volatile
Total Current Liabilities15.9 M15.1 MM
Slightly volatile
Accounts Payable672 K550.4 K356.7 K
Slightly volatile
Non Current Assets Total555.8 K720.5 K311.7 K
Slightly volatile
Non Currrent Assets Other418.3 K586 K283.8 K
Slightly volatile
Other Assets66.6 K74.9 K81.6 K
Slightly volatile
Common Stock Shares Outstanding41.5 M59.6 M33.1 M
Slightly volatile
Liabilities And Stockholders Equity28.8 M27.5 M7.7 M
Slightly volatile
Total Liabilities16 M15.2 M3.1 M
Slightly volatile
Deferred Long Term Liabilities66.6 K74.9 K81.6 K
Slightly volatile
Other Liabilities107.4 K120.8 K131.5 K
Slightly volatile
Cash And Short Term Investments27.1 M25.8 M8.3 M
Slightly volatile
Net Receivables262.7 K250.2 K68.1 K
Slightly volatile
Other Current Assets594.4 K602.9 K353.8 K
Slightly volatile
Other Stockholder Equity14.3 M13.6 M3.8 M
Slightly volatile
Accumulated Other Comprehensive Income14.3 M13.6 M3.8 M
Slightly volatile
Capital Stock36.8 M58.9 M17.9 M
Slightly volatile
Intangible Assets393.9 K520.8 K515.4 K
Slightly volatile
Common Stock69.3 M66 M20.5 M
Slightly volatile
Property Plant And Equipment Net137.4 K199.8 K43.8 K
Slightly volatile
Property Plant Equipment356.6 K339.6 K67.7 K
Slightly volatile
Short and Long Term Debt Total226.8 K255.1 K277.8 K
Slightly volatile
Property Plant And Equipment Gross198 K199.8 K282.4 K
Slightly volatile
Short Term Debt69 K77.6 K84.5 K
Slightly volatile

NervGen Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.9 M9.6 M2.4 M
Slightly volatile
Other Operating Expenses27.8 M26.5 M7.5 M
Slightly volatile
Total Operating Expenses11.9 M17.8 M5.9 M
Slightly volatile
Depreciation And Amortization139 K132.4 K45.7 K
Slightly volatile
Interest Income577.6 K550.1 K157.7 K
Slightly volatile
Cost Of Revenue139 K132.4 K56.7 K
Slightly volatile

NervGen Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation152.3 K145 K47.4 K
Slightly volatile
Capital Expenditures148.5 K141.4 K34.5 K
Slightly volatile
Total Cash From Financing Activities728 K766.3 K6.3 M
Slightly volatile
Stock Based Compensation3.2 MM1.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.2 M1.1 M513.8 K
Slightly volatile
Capex To Depreciation1.910.97524.1367
Slightly volatile
Payables Turnover0.280.26340.0989
Slightly volatile
Cash Per Share0.20.19670.1604
Slightly volatile
Days Payables Outstanding1.3 K1.4 K5.6 K
Slightly volatile
Income Quality0.770.50470.7377
Slightly volatile
Intangibles To Total Assets0.07460.03930.1264
Slightly volatile
Net Debt To EBITDA1.070.64681.4467
Slightly volatile
Current Ratio0.790.82675.743
Pretty Stable
Graham Number0.750.53650.4913
Slightly volatile
Capex Per Share0.00190.00240.0032
Slightly volatile
Average Receivables35.4 K41 K26.9 K
Slightly volatile
Interest Debt Per Share0.00780.00880.0096
Slightly volatile
Days Of Payables Outstanding1.3 K1.4 K5.6 K
Slightly volatile
Ebt Per Ebit0.821.25910.9917
Very volatile
Effective Tax Rate0.140.152.407
Slightly volatile
Quick Ratio0.790.82675.743
Pretty Stable
Net Income Per E B T1.061.00.9883
Very volatile
Cash Ratio0.730.77015.3913
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.01251.0832
Slightly volatile

NervGen Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap51.9 M96.5 M60.8 M
Slightly volatile
Enterprise Value47.2 M81.3 M56.4 M
Slightly volatile

About NervGen Pharma Financial Statements

NervGen Pharma investors use historical fundamental indicators, such as NervGen Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NervGen Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue132.4 K139 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NervGen Stock Analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.